This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Anti-GAD

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Anti-glutamic acid decarboxylase (GAD) antibodies have been associated with type 1 diabetes mellitus and a large variety of neurological conditions, including epilepsy (1).

GAD antibodies are also associated with other conditions such as Stiff Man syndrome.

The background frequency of anti-GAD antibodies in the general population has been assessed to be around 0.4-1% (2)

Reference:

  • Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008;131:2553-63
  • Batstra MR, van Driel A, Petersen JS, et al. Glutamic acid decarboxylase antibodies in screening for autoimmune diabetes: influence of comorbidity, age, and sex on specificity and threshold values. Clin Chem 1999;45:2269-72.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.